Lipoxin A4 Prevents the Progression of De Novo and Established Endometriosis in a Mouse Model by Attenuating Prostaglandin E2 Production and Estrogen Signaling
Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well as estrogen-mediated signaling and novel, improved therapeutics targeting these pathways are necessary. The aim of this study was to investigate mechanisms leading to the establishment and progression of endometriosis as well as the effect of local treatment with Lipoxin A4 (LXA4), an anti-inflammatory and pro-resolving lipid mediator that we have recently characterized as an estrogen receptor agonist. LXA4 treatment significantly reduced endometriotic lesion size and downregulated the pro-inflammatory cytokines IL-1β and IL-6, as well as the angiogenic factor VEGF. LXA4 also inhibited COX-2 expression in both endometriotic lesions and peritoneal fluid cells, resulting in attenuated peritoneal fluid Prostaglandin E2 (PGE2) levels. Besides its anti-inflammatory effects, LXA4 differentially regulated the expression and activity of the matrix remodeling enzyme matrix metalloproteinase (MMP)-9 as well as modulating transforming growth factor (TGF)-β isoform expression within endometriotic lesions and in peritoneal fluid cells. We also report for first time that LXA4 attenuated aromatase expression, estrogen signaling and estrogen-regulated genes implicated in cellular proliferation in a mouse model of disease. These effects were observed both when LXA4 was administered prior to disease induction and during established disease. Collectively, our findings highlight potential targets for the treatment of endometriosis and suggest a pleotropic effect of LXA4 on disease progression, by attenuating pro-inflammatory and angiogenic mediators, matrix remodeling enzymes, estrogen metabolism and signaling, as well as downstream proliferative pathways.
References
[1]
Eskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24: 235–258. doi: 10.1016/s0889-8545(05)70302-8
[2]
Bulun SE (2009) Endometriosis. The New England journal of medicine 360: 268–279. doi: 10.1056/nejmra0804690
[3]
Gruppo Italiano per lo Studio dE (2001) Relationship between stage, site and morphological characteristics of pelvic endometriosis and pain. Hum Reprod 16: 2668–2671. doi: 10.1093/humrep/16.12.2668
[4]
Waller KG, Shaw RW (1993) Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertility and sterility 59: 511–515. doi: 10.1097/00006254-199309000-00023
[5]
Vercellini P, Crosignani P, Somigliana E, Vigano P, Frattaruolo MP, et al. (2011) ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod 26: 3–13. doi: 10.1093/humrep/deq302
[6]
Harada T, Iwabe T, Terakawa N (2001) Role of cytokines in endometriosis. Fertility and sterility 76: 1–10. doi: 10.1016/s0015-0282(01)01816-7
[7]
Huhtinen K, Stahle M, Perheentupa A, Poutanen M (2012) Estrogen biosynthesis and signaling in endometriosis. Mol Cell Endocrinol 358: 146–154. doi: 10.1016/j.mce.2011.08.022
[8]
Dmowski WP, Ding J, Shen J, Rana N, Fernandez BB, et al. (2001) Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Hum Reprod 16: 1802–1808. doi: 10.1093/humrep/16.9.1802
[9]
Beliard A, Noel A, Foidart JM (2004) Reduction of apoptosis and proliferation in endometriosis. Fertility and sterility 82: 80–85. doi: 10.1016/j.fertnstert.2003.11.048
[10]
Oosterlynck DJ, Meuleman C, Waer M, Koninckx PR (1994) Transforming growth factor-beta activity is increased in peritoneal fluid from women with endometriosis. Obstet Gynecol 83: 287–292.
[11]
Sillem M, Prifti S, Koch A, Neher M, Jauckus J, et al. (2001) Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. European journal of obstetrics, gynecology, and reproductive biology 95: 167–174. doi: 10.1016/s0301-2115(00)00415-2
[12]
Serhan CN (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, leukotrienes, and essential fatty acids 73: 141–162. doi: 10.1016/j.plefa.2005.05.002
[13]
Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, et al. (2006) The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacological reviews 58: 463–487. doi: 10.1124/pr.58.3.4
[14]
Fiore S, Maddox JF, Perez HD, Serhan CN (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J? Exp Med 180: 253–260. doi: 10.1084/jem.180.1.253
[15]
Fiore S, Romano M, Reardon EM, Serhan CN (1993) Induction of functional lipoxin A4 receptors in HL-60 cells. Blood 81: 3395–3403.
[16]
Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, et al. (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proceedings of the National Academy of Sciences of the United States of America 107: 1660–1665. doi: 10.1073/pnas.0907342107
[17]
Schaldach CM, Riby J, Bjeldanes LF (1999) Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 38: 7594–7600. doi: 10.1021/bi982861e
[18]
Russell R, Gori I, Pellegrini C, Kumar R, Achtari C, et al. (2011) Lipoxin A4 is a novel estrogen receptor modulator. FASEB? J 25: 4326–4337. doi: 10.1096/fj.11-187658
[19]
Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, et al. (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. Journal of the American Society of Nephrology: JASN 13: 2497–2507. doi: 10.1097/01.asn.0000032417.73640.72
[20]
Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nature immunology 6: 1191–1197. doi: 10.1038/ni1276
[21]
Wu MH, Shoji Y, Wu MC, Chuang PC, Lin CC, et al. (2005) Suppression of matrix metalloproteinase-9 by prostaglandin E(2) in peritoneal macrophage is associated with severity of endometriosis. Am? J? Pathol 167: 1061–1069. doi: 10.1016/s0002-9440(10)61195-9
[22]
Chen QH, Zhou WD, Pu DM, Huang QS, Li T, et al. (2010) 15-Epi-lipoxin A(4) inhibits the progression of endometriosis in a murine model. Fertility and sterility 93: 1440–1447. doi: 10.1016/j.fertnstert.2009.01.107
[23]
Xu Z, Zhao F, Lin F, Chen J, Huang Y (2012) Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis. Am? J? Reprod Immunol 67: 491–497. doi: 10.1111/j.1600-0897.2011.01101.x
[24]
Vernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertility and sterility 44: 684–694.
[25]
Cummings AM, Metcalf JL (1995) Induction of endometriosis in mice: a new model sensitive to estrogen. Reproductive toxicology 9: 233–238. doi: 10.1016/0890-6238(95)00004-t
[26]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. doi: 10.1006/meth.2001.1262
[27]
Becker CM, D'Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvascular research 74: 121–130. doi: 10.1016/j.mvr.2007.04.008
[28]
Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI, et al. (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95: 1055–1063. doi: 10.1002/cncr.10774
[29]
Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, et al. (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci? U? S? A 100: 9244–9249. doi: 10.1073/pnas.1033060100
[30]
Dunselman GA, Hendrix MG, Bouckaert PX, Evers JL (1988) Functional aspects of peritoneal macrophages in endometriosis of women. J? Reprod Fertil 82: 707–710. doi: 10.1530/jrf.0.0820707
[31]
Lin YJ, Lai MD, Lei HY, Wing LY (2006) Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 147: 1278–1286. doi: 10.1210/en.2005-0790
[32]
Jones RL, Stoikos C, Findlay JK, Salamonsen LA (2006) TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 132: 217–232. doi: 10.1530/rep.1.01076
[33]
Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, et al. (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15: 342–355. doi: 10.1210/edrv-15-3-342
[34]
Haining RE, Cameron IT, van Papendorp C, Davenport AP, Prentice A, et al. (1991) Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues. Hum Reprod 6: 1200–1205.
[35]
Resnitzky D, Reed SI (1995) Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 15: 3463–3469.
[36]
Pelengaris S, Khan M, Evan G (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764–776. doi: 10.1038/nrc904
[37]
Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: MarvelouslY Complex. Adv Cancer Res 84: 81–154. doi: 10.1016/s0065-230x(02)84004-0
[38]
Ghosh MG, Thompson DA, Weigel RJ (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer research 60: 6367–6375.
[39]
Pellegrini C, Gori I, Achtari C, Hornung D, Chardonnens E, et al. (2012) The expression of estrogen receptors as well as GREB1, c-MYC, and cyclin D1, estrogen-regulated genes implicated in proliferation, is increased in peritoneal endometriosis. Fertility and sterility 98: 1200–1208. doi: 10.1016/j.fertnstert.2012.06.056
[40]
Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, et al. (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92: 141–149. doi: 10.1007/s10549-005-1483-4
[41]
Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature reviews Immunology 8: 349–361. doi: 10.1038/nri2294
[42]
Grummer R (2006) Animal models in endometriosis research. Hum Reprod Update 12: 641–649. doi: 10.1093/humupd/dml026
[43]
Chen Q, Zhou W, Pu D, Li Z, Huang Q, et al. (2009) The inhibitory effect of 15-R-LXA4 on experimental endometriosis. European journal of obstetrics, gynecology, and reproductive biology 145: 200–204. doi: 10.1016/j.ejogrb.2009.05.015
[44]
Shay JE, Celeste Simon M (2012) Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin Cell Dev Biol 23: 389–394. doi: 10.1016/j.semcdb.2012.04.004
[45]
Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, et al. (2008) 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am? J? Pathol 172: 534–544. doi: 10.2353/ajpath.2008.061244
[46]
Mahnke JL, Dawood MY, Huang JC (2000) Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertility and sterility 73: 166–170. doi: 10.1016/s0015-0282(99)00466-5
[47]
Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M (2010) Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertility and sterility 94: 52–57. doi: 10.1016/j.fertnstert.2009.02.019
[48]
Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thijssen VL, et al. (2004) Antiangiogenesis therapy for endometriosis. J? Clin Endocrinol Metab 89: 1089–1095. doi: 10.1210/jc.2003-031406
[49]
Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD (2006) Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 21: 262–268. doi: 10.1093/humrep/dei308
[50]
Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Baranao RI (2011) Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci 18: 614–622. doi: 10.1177/1933719110395406
[51]
Ota H, Igarashi S, Sasaki M, Tanaka T (2001) Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16: 561–566. doi: 10.1093/humrep/16.3.561
[52]
Tamura M, Sebastian S, Yang S, Gurates B, Fang Z, et al. (2002) Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. J? Clin Endocrinol Metab 87: 3263–3273. doi: 10.1210/jcem.87.7.8594
[53]
Tamura M, Sebastian S, Yang S, Gurates B, Ferrer K, et al. (2002) Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A? paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B.? J? Biol Chem 277: 26208–26216. doi: 10.1074/jbc.m201347200
[54]
Bulun SE, Zeitoun KM, Takayama K, Sasano H (2000) Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J? Mol Endocrinol 25: 35–42. doi: 10.1677/jme.0.0250035
[55]
Gori I, Rodriguez Y, Pellegrini C, Achtari C, Hornung D, et al.. (2013) Augmented epithelial multidrug resistance-associated protein 4 expression in peritoneal endometriosis: regulation by lipoxin A(4). Fertil Steril 99: 1965–1973 e1962.
[56]
Felsher DW, Bishop JM (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci? U? S? A 96: 3940–3944. doi: 10.1073/pnas.96.7.3940
[57]
Shimizu Y, Takeuchi T, Mita S, Mizuguchi K, Kiyono T, et al. (2009) Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 15: 693–701. doi: 10.1093/molehr/gap042
[58]
Fu L, Osuga Y, Morimoto C, Hirata T, Hirota Y, et al. (2008) Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertility and sterility 89: 1344–1347. doi: 10.1016/j.fertnstert.2007.03.042
[59]
Velarde MC, Aghajanova L, Nezhat CR, Giudice LC (2009) Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3′,5′-cyclic adenosine 5′-monophosphate inhibition of cyclin D1. Endocrinology 150: 4701–4712. doi: 10.1210/en.2009-0389
[60]
Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, et al. (2012) Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet 44: 1355–1359. doi: 10.1038/ng.2445
[61]
Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, et al. (2012) Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 119: 411–421. doi: 10.1182/blood-2011-02-339911
[62]
Johnson MC, Torres M, Alves A, Bacallao K, Fuentes A, et al. (2005) Augmented cell survival in eutopic endometrium from women with endometriosis: expression of c-myc, TGF-beta1 and bax genes. Reprod Biol Endocrinol 3: 45.
[63]
Meola J, Rosa e Silva JC, Dentillo DB, da Silva WA, Veiga-Castelli LC, et al. (2010) Differentially expressed genes in eutopic and ectopic endometrium of women with endometriosis. Fertility and sterility 93: 1750–1773. doi: 10.1016/j.fertnstert.2008.12.058
[64]
Clark JH, Markaverich BM (1984) The agonistic and antagonistic actions of estriol. J? Steroid Biochem 20: 1005–1013. doi: 10.1016/0022-4731(84)90011-6
[65]
Melamed M, Castano E, Notides AC, Sasson S (1997) Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol 11: 1868–1878. doi: 10.1210/mend.11.12.0025
[66]
Burns KA, Rodriguez KF, Hewitt SC, Janardhan KS, Young SL, et al. (2012) Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. Endocrinology 153: 3960–3971. doi: 10.1210/en.2012-1294
[67]
Gronert K, Gewirtz A, Madara JL, Serhan CN (1998) Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. The Journal of experimental medicine 187: 1285–1294. doi: 10.1084/jem.187.8.1285
[68]
Hashimoto A, Hayashi I, Murakami Y, Sato Y, Kitasato H, et al. (2007) Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J? Rheumatol 34: 2144–2153.
[69]
Pelch KE, Schroder AL, Kimball PA, Sharpe-Timms KL, Davis JW, et al.. (2010) Aberrant gene expression profile in a mouse model of endometriosis mirrors that observed in women. Fertil Steril 93: 1615–1627 e1618.
[70]
Polli V, Bulletti C, Galassi A, Borini A, Ciotti PM, et al. (1996) Transforming growth factor-beta 1 in the human endometrium. Gynecol Endocrinol 10: 297–302. doi: 10.3109/09513599609012815
[71]
Kupker W, Schultze-Mosgau A, Diedrich K (1998) Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update 4: 719–723. doi: 10.1093/humupd/4.5.719
[72]
Sotnikova NY, Antsiferova YS, Posiseeva LV, Shishkov DN, Posiseev DV, et al. (2010) Mechanisms regulating invasiveness and growth of endometriosis lesions in rat experimental model and in humans. Fertility and sterility 93: 2701–2705. doi: 10.1016/j.fertnstert.2009.11.024
[73]
Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N? Engl? J? Med 342: 1350–1358. doi: 10.1056/nejm200005043421807
Streuli I, de Ziegler D, Santulli P, Marcellin L, Borghese B, et al. (2013) An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 14: 291–305. doi: 10.1517/14656566.2013.767334
